Henrike Feuersenger

924 total citations
30 papers, 233 citations indexed

About

Henrike Feuersenger is a scholar working on Genetics, Hematology and Nutrition and Dietetics. According to data from OpenAlex, Henrike Feuersenger has authored 30 papers receiving a total of 233 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Genetics, 17 papers in Hematology and 8 papers in Nutrition and Dietetics. Recurrent topics in Henrike Feuersenger's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (29 papers), Hemophilia Treatment and Research (15 papers) and Vitamin K Research Studies (8 papers). Henrike Feuersenger is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (29 papers), Hemophilia Treatment and Research (15 papers) and Vitamin K Research Studies (8 papers). Henrike Feuersenger collaborates with scholars based in United States, Germany and Italy. Henrike Feuersenger's co-authors include Timothy Craig, Jonathan A. Bernstein, Ingo Pragst, Marco Cicardi, Jonathan M. Edelman, Markus Magerl, Dipti Pawaskar, Marc A. Riedl, Hilary Longhurst and Bruce L. Zuraw and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Allergy and Annals of Allergy Asthma & Immunology.

In The Last Decade

Henrike Feuersenger

25 papers receiving 222 citations

Peers

Countries citing papers authored by Henrike Feuersenger

Since Specialization

Citations

This map shows the geographic impact of Henrike Feuersenger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrike Feuersenger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrike Feuersenger more than expected).

Fields of papers citing papers by Henrike Feuersenger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrike Feuersenger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrike Feuersenger. The network helps show where Henrike Feuersenger may publish in the future.

Co-authorship network of co-authors of Henrike Feuersenger

This figure shows the co-authorship network connecting the top 25 collaborators of Henrike Feuersenger. A scholar is included among the top collaborators of Henrike Feuersenger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrike Feuersenger. Henrike Feuersenger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Garadacimab in hereditary angioedema due to normal C1INH with F12/PLG mutations 2025 ·Journal of Allergy and Clinical Immunology ·Danny M. Cohn, (unknown), Petra Staubach, William R. Lumry, Henrike Feuersenger, Iris Jacobs, Ingo Pragst, Bruce L. Zuraw, Konrad Bork	0
2	Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study 2024 ·The Lancet Haematology ·Timothy Craig, Donald S. Levy, Avner Reshef, William R. Lumry, Inmaculada Martinez‐Saguer, Joshua Jacobs, William H. Yang, Bruce Ritchie, Emel Aygören‐Pürsün, Paul K. Keith, Paula J. Busse, Henrike Feuersenger, (unknown), Iris Jacobs, Ingo Pragst, Markus Magerl	8
3	Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema 2022 ·Allergy and Asthma Proceedings ·Timothy Craig, Henrike Feuersenger, Ingo Pragst, (unknown)	8
4	A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab 2021 ·Clinical and Translational Science ·(unknown), Anthony Roberts, (unknown), Henrike Feuersenger, Con Panousis, Dipti Pawaskar	26
5	Weight-based Dosing of Subcutaneous C1-Inhibitor Facilitates Management of Hereditary Angioedema in Obese Patients 2020 ·Journal of Allergy and Clinical Immunology ·(unknown), Timothy Craig, Henrike Feuersenger	0
6	Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema 2020 ·Pediatric Allergy Immunology and Pulmonology ·Donald S. Levy, Teresa Caballero, Iftikhar Hussaın, Avner Reshef, John Anderson, James Baker, Lawrence B. Schwartz, Marco Cicardi, (unknown), Henrike Feuersenger, Ingo Pragst, Michael Manning	16
7	Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial 2020 ·Allergy Asthma and Clinical Immunology ·Donald S. Levy, Henriette Farkas, Marc A. Riedl, Florence Ida Hsu, (unknown), Marco Cicardi, Henrike Feuersenger, Ingo Pragst, Avner Reshef	14
8	Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema 2020 ·Annals of Allergy Asthma & Immunology ·Jonathan A. Bernstein, Lawrence B. Schwartz, William H. Yang, James Baker, John Anderson, Henriette Farkas, Emel Aygören‐Pürsün, Anette Bygum, Iris Jacobs, Henrike Feuersenger, Ingo Pragst, Marc A. Riedl	11
9	Long-term Safety of Subcutaneous C1-Inhibitor in the Prophylactic Treatment of Hereditary Angioedema 2019 ·Journal of Allergy and Clinical Immunology ·H. Henry Li, Timothy Craig, Hilary Longhurst, Marco Cicardi, Henrike Feuersenger, Ingo Pragst, (unknown)	3
10	Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study 2019 ·Allergy Asthma and Clinical Immunology ·H. Henry Li, Bruce L. Zuraw, Hilary Longhurst, Marco Cicardi, Konrad Bork, James Baker, William R. Lumry, Jonathan A. Bernstein, Michael Manning, Donald S. Levy, Marc A. Riedl, Henrike Feuersenger, (unknown), Ingo Pragst, Thomas Machnig, Timothy Craig, (unknown)	9
11	Initiation of Prophylactic Treatment with Subcutaneous C1-Esterase Inhibitor (C1-INH [SC]) for Prevention of Hereditary Angioedema (HAE) Attacks and Onset of Effect: Findings from the Phase III COMPACT Study 2018 ·Journal of Allergy and Clinical Immunology ·(unknown), Marc A. Riedl, Timothy Craig, Hilary Longhurst, Marco Cicardi, Bruce L. Zuraw, Henrike Feuersenger	1
12	LONG-TERM EFFICACY OF SUBCUTANEOUS C1 INHIBITOR IN PEDIATRIC PATIENTS WITH HEREDITARY ANGIOEDEMA 2018 ·Annals of Allergy Asthma & Immunology ·Michael Manning, Teresa Caballero, Iftikhar Hussaın, Henrike Feuersenger, (unknown), Ian N. Jacobs, Ingo Pragst	1
13	Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial 2018 ·Allergy and Asthma Proceedings ·(unknown), (unknown), Sandra C. Christiansen, Daniel Wood, Henrike Feuersenger, Dipti Pawaskar, Iris Jacobs	11
14	LONG-TERM EFFICACY AND SAFETY OF SUBCUTANEOUS C1-INHIBITOR IN ELDERLY PATIENTS WITH HEREDITARY ANGIOEDEMA TYPE I/II 2018 ·Annals of Allergy Asthma & Immunology ·Jonine L. Bernstein, L Schwartz, Henrike Feuersenger, Ingo Pragst, (unknown), Ian N. Jacobs	0
15	Health-Related Quality of Life (HRQoL) and Changes in Work Productivity Measures with Subcutaneous C1-Inhibitor [C1-INH(SC)] for the Prevention of Hereditary Angioedema (HAE) Attacks: Findings from the Compact Study 2017 ·Journal of Allergy and Clinical Immunology ·William R. Lumry, Timothy Craig, Henriette Farkas, Henrike Feuersenger	1
16	Subcutaneous C1-Esterase Inhibitor [C1-INH(SC)] to Prevent Hereditary Angioedema (HAE) Attacks: Subject and Investigator Assessments from the Compact Trial 2017 ·Journal of Allergy and Clinical Immunology ·Hilary Longhurst, (unknown), Marc A. Riedl, Timothy Craig, Avner Reshef, Henriette Farkas, Henrike Feuersenger, Daniel Wood, Douglas J. Watson, Ingo Pragst	1
17	Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor 2016 ·Annals of Allergy Asthma & Immunology ·Henriette Farkas, Lilian Varga, Dumitru Moldovan, Krystyna Obtułowicz, (unknown), Thomas Machnig, Henrike Feuersenger, Jonathan M. Edelman, Debora Williams‐Herman, Mikhail Rojavin	6
18	Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema 2016 ·Annals of Allergy Asthma & Immunology ·Markus Magerl, Michael J. Frank, William R. Lumry, Jonathan A. Bernstein, Paula J. Busse, Timothy Craig, Inmaculada Martinez‐Saguer, Marc A. Riedl, Ralph Shapiro, Jonathan M. Edelman, Debora Williams‐Herman, Daniel Wood, Henrike Feuersenger, Mikhail Rojavin	19
19	Efficacy and Safety of a C1 Esterase Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary Angioedema: Findings from a Large International Registry 2015 ·Journal of Allergy and Clinical Immunology ·Timothy Craig, Jonathan M. Edelman, Henrike Feuersenger, Michael M. Frank, Mikhail Rojavin, Ralph Shapiro, (unknown), Walter A. Wuillemin	0
20	Predictive value of B-type natriuretic peptide levels in patients with paroxysmal and persistent atrial fibrillation undergoing pulmonary vein isolation 2011 ·Journal of Interventional Cardiac Electrophysiology ·Stephan Degener, (unknown), Henrike Feuersenger, Paul M. Bansmann, Dong‐In Shin, Frank Krummenauer, Marc Horlitz	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact